Development of antileishmanial lipid nanocomplexes

Biochimie

Volumn 107, Issue Part A, 2014, Pages 143-153

  Pham, T T H ^a,d   Gueutin, C ^a   Cheron, M ^b   Abreu, S ^c   Chaminade, P ^c   Loiseau, P M ^d   Barratt, G ^a  

^a INSTITUT CURIE   (France)

^b CNRS   (France)

^c University Paris Saclay   (France)

^d UNIVERSITÉ PARIS SUD   (France)

Author keywords

Amphotericin B Miltefosine Oral route Visceral leishmaniasis; Nanocochleates

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; DIOLEOYLPHOSPHATIDYLSERINE; MILTEFOSINE; 1,2-DIOLEOYLPHOSPHATIDYLSERINE; ANTIPROTOZOAL AGENT; CALCIUM; CHOLESTEROL; LIPID; LIPOSOME; NANOCOMPOSITE; PHOSPHATIDYLSERINE; PHOSPHORYLCHOLINE;

ARTICLE; CIRCULAR DICHROISM; DRUG FORMULATION; DRUG RELEASE; GASTROINTESTINAL TRACT; HYDRODYNAMICS; IN VITRO STUDY; LIPID BILAYER; LIPID MONOLAYER; MASS SPECTROMETRY; PARTICLE SIZE; REVERSE OSMOSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ROOM TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY; VISCERAL LEISHMANIASIS; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG STABILITY; HUMAN; LEISHMANIASIS, VISCERAL; ORAL DRUG ADMINISTRATION; PARASITOLOGY; PROCEDURES; SPECTROPHOTOMETRY; ULTRASTRUCTURE;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; CALCIUM; CHOLESTEROL; CIRCULAR DICHROISM; DRUG COMPOUNDING; DRUG STABILITY; HUMANS; LEISHMANIASIS, VISCERAL; LIPIDS; LIPOSOMES; MICROSCOPY, ELECTRON, TRANSMISSION; NANOCOMPOSITES; PARTICLE SIZE; PHOSPHATIDYLSERINES; PHOSPHORYLCHOLINE; SPECTROPHOTOMETRY;

EID: 84915735645     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2014.06.007     Document Type: Article

References (50)

1. P. Desjeux Leishmaniasis: public health aspects and control Clin. Dermatol. 14 1996 417 423
2. B.L. Herwaldt Leishmaniasis Lancet 354 1999 1191 1199
3. P. Desjeux Leishmaniasis: current situation and new perspectives, comparative immunology Microbiol. Infect. Dis. 27 2004 305 318
4. P. Desjeux The increase in risk factors for leishmaniasis worldwide Trans. R. Soc. Trop. Med. Hyg. 95 2001 239 243
5. S. Sundar, and M. Rai Laboratory diagnosis of visceral leishmaniasis Clin. Diagn. Lab. Immunol. 9 2002 951 958
6. J. Alvar, S. Croft, P. Olliaro, and H.M. David Chemotherapy in the treatment and control of leishmaniasis Advances in Parasitology 2006 Academic Press 223 274
7. J. Berman Recent developments in leishmaniasis: epidemiology, diagnosis, and treatment Curr. Infect. Dis. Rep. 7 2005 33 38
8. S. Sundar, F. Rosenkaimer, M.K. Makharia, A.K. Goyal, A.K. Mandal, A. Voss, P. Hilgard, and H.W. Murray Trial of oral miltefosine for visceral leishmaniasis Lancet 352 1998 1821 1823
9. P.J. Guerin, P. Olliaro, S. Sundar, M. Boelaert, S.L. Croft, P. Desjeux, M.K. Wasunna, and A.D.M. Bryceson Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda Lancet Infect. Dis. 2 2002 494 501
10. F.J. Pérez-Victoria, M.P. Sánchez-Canete, K. Seifert, S.L. Croft, S. Sundar, S. Castanys, and F. Gamarro Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use Drug. Resist. Updat. 9 2006 26 39
11. D. Papahadjopoulos, W.J. Vail, K. Jacobson, and G. Poste Cochleate lipid cylinders: formation by fusion of unilamellar lipid vesicles Biochim. Biophys. Acta (BBA) - Biomembranes 394 1975 483 491
12. D. Papahadjopoulos, A. Portis, and W. Pangborn Calcium-induced lipid phase transition and membrane fusion Ann. N. Y. Acad. Sci. 308 1978 50 66
13. L. Zarif Drug delivery by lipid cochleates Meth. Enzymol. 391 2005 314 329
14. R.J. Mannino, M. Canki, E. Feketeova, A.J. Scolpino, Z. Wang, F. Zhang, M.T. Kheiri, and S. Gould-Fogerite Targeting immune response induction with cochleate and liposome-based vaccines Adv. Drug Deliv. Rev. 32 1998 273 287
15. R. Santangelo, P. Paderu, G. Delmas, Z.W. Chen, R. Mannino, L. Zarif, and D.S. Perlin Efficacy of oral cochleate-Amphotericin B in a mouse model of systemic candidiasis Antimicrob. Agents Chemother. 44 2000 2356 2360
16. L. Zarif, J.R. Graybill, D. Perlin, L. Najvar, R. Bocanegra, and R.J. Mannino Antifungal activity of Amphotericin B cochleates against Candida albicans infection in a mouse model Antimicrob. Agents Chemother. 44 2000 1463 1469
17. G. Delmas, S. Park, Z.W. Chen, F. Tan, R. Kashiwazaki, L. Zarif, and D.S. Perlin Efficacy of orally delivered cochleates containing Amphotericin B in a murine model of aspergillosis Antimicrob. Agents Chemother. 46 2002 2704 2707
18. L. Zarif, J.R. Graybill, D. Perlin, and R.J. Mannino Cochleates: new lipid-based drug delivery system J. Liposome Res. 10 2000 523 538
19. T. Jin, L. Zarif, R.J. Mannino, Nano-cochleate formulations, process of preparation and method of delivery of pharmaceutical agents, U.S.A., 2000.
20. C. Ménez, M. Buyse, M. Besnard, R. Farinotti, P.M. Loiseau, and G. Barratt Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro Antimicrob. Agents Chemother. 50 2006 3793 3800
21. T.P.C. Dorlo, M.J.X. Hillebrand, H. Rosing, T.A. Eggelte, P.J. de Vries, and J.H. Beijnen Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry J. Chromatogr. B 865 2008 55 62
22. US Pharmacopeia, U. Rockville, MD, 2006.
23. M. Rakotomanga, P.M. Loiseau, and M. Saint-Pierre-Chazalet Hexadecylphosphocholine interaction with lipid monolayers Biochim. Biophys. Acta (BBA) - Biomembranes 1661 2004 212 218
24. P. Méléard, C. Gerbeaud, T. Pott, L. Fernandez-Puente, I. Bivas, M.D. Mitov, J. Dufourcq, and P. Bothorel Bending elasticities of model membranes: influences of temperature and sterol content Biophys. J. 72 1997 2616 2629
25. G. Orädd, V. Shahedi, and G. Lindblom Effect of sterol structure on the bending rigidity of lipid membranes: a 2H NMR transverse relaxation study Biochim. Biophys. Acta (BBA) - Biomembranes 1788 2009 1762 1771
26. C. Decker, A. Fahr, J. Kuntsche, and S. May Selective partitioning of cholesterol and a model drug into liposomes of varying size Chem. Phys. Lipids 165 2012 520 529
27. J. Pan, S. Tristram-Nagle, and J.F. Nagle Effect of cholesterol on structural and mechanical properties of membranes depends on lipid chain saturation Phys. Rev. E Stat. Nonlin. Soft Matter Phys. 80 2009 021931
28. T.T. Pham, G. Barratt, J.P. Michel, P.M. Loiseau, and M. Saint-Pierre-Chazalet Interactions of antileishmanial drugs with monolayers of lipids used in the development of amphotericin B-miltefosine-loaded nanocochleates Colloids Surf. B Biointerfaces 106 2013 224 233
29. C.W. Pouton Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 29 2006 278 287
30. F. Kesisoglou, S. Panmai, and Y. Wu Nanosizing-oral formulation development and biopharmaceutical evaluation Adv. Drug Deliv. Rev. 59 2007 631 644
31. L. Zarif, T. Jin, I. Segarra, and R.J. Mannino Hydrogel-isolated Cochleate Formulations, Process of Preparation and Their Use for the Delivery of Biologically Relevant Molecules 2003 BioDelivery Sciences International, Inc., University of Medicine and Dentistry of New Jersey U.S.A.
32. L.M. Crowe, J.H. Crowe, A. Rudolph, C. Womersley, and L. Appel Preservation of freeze-dried liposomes by trehalose Arch. Biochem. Biophys. 242 1985 240 247
33. J. Bolard, M. Cheron, and J. Mazerski Effect of surface curvature on the interaction of single lamellar phospholipid vesicles with aromatic and nonaromatic heptaene antibiotics (vacidin A and amphotericin B) Biochem. Pharmacol. 33 1984 3675 3680
34. M.S. Espuelas, P. Legrand, M. Cheron, G. Barratt, F. Puisieux, J.P. Devissaguet, and J.M. Irache Interaction of amphotericin B with polymeric colloids: a spectroscopic study Colloids Surf. B Biointerfaces 11 1998 141 151
35. M.S. Espuelas, P. Legrand, M. Cheron, G. Barratt, F. Puisieux, M.J. Renedo, J.P. Devissaguet, and J.M. Irache Interaction of amphotericin B with polymeric colloids: 2. Effect of poloxamer on the adsorption of amphotericin B onto poly(epsilon-caprolactone) nanospheres Colloids Surf. B Biointerfaces 11 1998 203 212
36. F. Gaboriau, M. Cheron, C. Petit, and J. Bolard Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index Antimicrob. Agents Chemother. 41 1997 2345 2351
37. J. Barwicz, W.I. Gruszecki, and I. Gruda Spontaneous organization of Amphotericin B in aqueous medium J. Colloid Interface Sci. 158 1993 71 76
38. P. Legrand, E.A. Romero, B.E. Cohen, and J. Bolard Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes Antimicrob. Agents Chemother. 36 1992 2518 2522
39. P. Legrand, M. Cheron, L. Leroy, and J. Bolard Release of amphotericin B from delivery systems and its action against fungal and mammalian cells J. Drug Target 4 1997 311 319
40. S.M. Kelly, and N.C. Price The use of circular dichroism in the investigation of protein structure and function Curr. Protein Pept. Sci. 1 2000 349 384
41. J. Bolard, M. Seigneuret, and G. Boudet Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B: lipid state and cholesterol content dependence Biochim. Biophys. Acta (BBA) - Biomembranes 599 1980 280 293
42. J. Bolard, and M. Cheron Association of the polyene antibiotic amphotericin B with phospholipid vesicles: perturbation by temperature changes Can. J. Biochem. 60 1982 782 789
43. J. Bolard, P. Legrand, F. Heitz, and B. Cybulska One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium Biochemistry 30 1991 5707 5715
44. A. Vertut-Croquin, J. Bolard, M. Chabbert, and C. Gary-Bobo Differences in the interaction of the polyene antibiotic amphotericin B with cholesterol- or ergosterol-containing phospholipid vesicles. A circular dichroism and permeability study Biochemistry 22 1983 2939 2944
45. H. Binder, and O. Zschörnig The effect of metal cations on the phase behavior and hydration characteristics of phospholipid membranes Chem. Phys. Lipids 115 2002 39 61
46. J.K. Embleton, and C.W. Pouton Structure and function of gastro-intestinal lipases Adv. Drug Deliv. Rev. 25 1997 15 32
47. K. Andrieux, L. Forte, S. Lesieur, M. Paternostre, M. Ollivon, and C. Grabielle-Madelmont Solubilisation of dipalmitoylphosphatidylcholine bilayers by sodium taurocholate: a model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile salt Eur. J. Pharm. Biopharm. 71 2009 346 355
48. S. Ouadahi, M. Paternostre, C. Andre, I. Genin, T.X. Thao, F. Puisieux, J.P. Devissaguet, and G. Barratt Liposomal formulations for oral immunotherapy: in-vitro stability in synthetic intestinal media and in-vivo efficacy in the mouse J. Drug Target 5 1998 365 378
49. M. Mikov, J.P. Fawcett, K. Kuhajda, and S. Kevresan Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents Eur. J. Drug. Metab. Pharmacokinet. 31 2006 237 251
50. J.S. Dangi, S.P. Vyas, and V.K. Dixit Effect of various lipid-bile salt mixed micelles on the intestinal absorption of Amphotericin B in rat Drug. Dev. Ind. Pharm. 24 1998 631 635